Malignant Fibrous Histiocytoma (UPS): Undifferentiated Pleomorphic Sarcoma — Overview, Diagnosis & Treatment Options | MyMedicPlus

Malignant fibrous histiocytoma (MFH), now reclassified as undifferentiated pleomorphic sarcoma (UPS), was historically the most commonly diagnosed soft tissue sarcoma in adults. Under WHO 2013 and 2020 classifications, MFH is no longer recognized as a distinct entity; the diagnosis is now UPS, a high-grade sarcoma showing no line of differentiation by immunohistochemistry or molecular analysis. UPS represents approximately 20% of all soft tissue sarcomas and predominantly occurs in adults aged 50-70 years, most commonly in the extremities. Malignant Fibrous Histiocytoma (UPS): Undifferentiated Pleomorphic Sarcoma is a medical condition that affects patients across various age groups and demographics. It requires proper medical attention and management. This page provides evidence-based information about Malignant Fibrous Histiocytoma (UPS): Undifferentiated Pleomorphic Sarcoma to help patients understand the condition, its causes, symptoms, and available treatment options.

Most UPS cases are sporadic without identifiable cause. Prior therapeutic radiation to any anatomical site is a recognized risk factor for radiation-induced UPS, with a latency period of 5-30 years. Li-Fraumeni syndrome (TP53 germline mutation), NF1, and retinoblastoma syndrome increase sarcoma risk including UPS. Complex genomic instability (numerous chromosomal gains and losses without recurrent translocations) is the hallmark of UPS. TP53 mutations are found in approximately 30-40% of UPS. CDKN2A homozygous deletion and RB1 loss are common. No established environmental or dietary risk factors exist for sporadic UPS. The causes of Malignant Fibrous Histiocytoma (UPS): Undifferentiated Pleomorphic Sarcoma are often multifactorial, involving a combination of genetic predisposition, environmental exposures, and lifestyle factors. In some cases, infectious agents, immune dysfunction, or metabolic imbalances may contribute. Risk factors vary but may include age, sex, family history, and pre-existing medical conditions. Understanding the causes guides prevention strategies and informs treatment choices.

UPS typically presents as a deep-seated, painless or minimally painful enlarging soft tissue mass in the extremity or retroperitoneum. Extremity UPS often crosses fascial planes and may involve adjacent neurovascular structures with time. Retroperitoneal UPS may grow to large sizes (greater than 10 cm) before causing symptoms: abdominal pain, nausea, early satiety, or compression of adjacent organs. Constitutional symptoms (weight loss, fatigue) suggest advanced disease. Pathological fracture may be a presenting feature when UPS arises adjacent to bone. Symptoms of Malignant Fibrous Histiocytoma (UPS): Undifferentiated Pleomorphic Sarcoma can range from mild to severe and may develop gradually or appear suddenly. Common presentations include pain, inflammation, or functional impairment related to the affected system. Symptoms may fluctuate over time with periods of remission and exacerbation. Consult a healthcare provider if symptoms persist or worsen, as early diagnosis improves outcomes.

MRI with gadolinium is the preferred imaging for local staging, delineating tumor compartmentalization and neurovascular proximity. CT of chest, abdomen, and pelvis evaluates for pulmonary and hepatic metastases. Core needle biopsy in the planned resection plane is the diagnostic standard; surgical excisional biopsy risks compromising subsequent R0 resection. Histology shows a highly pleomorphic spindle and epithelioid cell tumor with no identifiable differentiation by immunohistochemistry (negative for actin, desmin, S100, CD34, MDM2, SOX10, MUC4). FNCLCC grading (grade 2 or 3 in UPS) and AJCC 8th edition TNM staging guide management. Diagnosis of Malignant Fibrous Histiocytoma (UPS): Undifferentiated Pleomorphic Sarcoma typically involves a thorough clinical history, physical examination, and targeted investigations. Laboratory tests, imaging studies, or specialist referrals may be required to confirm the diagnosis. Accurate diagnosis is essential for appropriate management and prevents unnecessary treatment.

Wide excision with negative margins (R0) is the cornerstone of curative treatment. Extremity UPS: limb-preserving surgery with pre-operative (50Gy) or post-operative (60-66Gy) radiation for high-grade tumors greater than 5 cm; amputation reserved for unresectable cases. Retroperitoneal UPS: aggressive resection of contiguous organs to achieve R0 margins if feasible. Adjuvant doxorubicin-based chemotherapy for high-risk UPS is used based on institutional practice. Metastatic UPS: doxorubicin monotherapy or doxorubicin plus ifosfamide; gemcitabine plus docetaxel; trabectedin; eribulin; pazopanib. Immunotherapy (pembrolizumab) shows modest activity in selected patients. Treatment of Malignant Fibrous Histiocytoma (UPS): Undifferentiated Pleomorphic Sarcoma is tailored to the individual and depends on severity and underlying cause. Options may include medications, lifestyle modifications, surgical interventions, or supportive therapies. Multidisciplinary care is often recommended for complex cases. The goal is to alleviate symptoms, slow disease progression, and improve quality of life.

Five-year overall survival for localized extremity UPS is approximately 50-60%; retroperitoneal UPS approximately 30-40% due to challenges achieving R0 resection. FNCLCC grade is the most important prognostic factor; all UPS are grade 2-3 (high-grade). Tumor size greater than 5 cm, depth (deep vs superficial), retroperitoneal location, and positive surgical margins are adverse prognostic factors. Approximately 40-50% of patients with localized high-grade UPS develop distant metastases, predominantly to the lungs, within 2-3 years. Median OS for metastatic UPS is approximately 12-16 months. The prognosis for Malignant Fibrous Histiocytoma (UPS): Undifferentiated Pleomorphic Sarcoma varies depending on severity at diagnosis, the patient's overall health, and how promptly treatment is initiated. With early diagnosis and appropriate management, many patients achieve good outcomes and maintain quality of life. Regular follow-up with healthcare providers is essential to monitor progress, adjust treatment as needed, and detect any complications early. Adherence to prescribed treatments and lifestyle modifications significantly improves long-term prognosis.

No prevention strategies exist for sporadic UPS. Avoidance of unnecessary therapeutic radiation minimizes radiation-induced sarcoma risk. Patients with hereditary predisposing syndromes (Li-Fraumeni syndrome, NF1, retinoblastoma) should undergo annual whole-body MRI surveillance starting in childhood or early adulthood. Unexplained soft tissue masses greater than 5 cm, or deep to fascia regardless of size, or rapidly enlarging masses, should be urgently referred to a specialist sarcoma center for evaluation and biopsy planning rather than excision in a non-specialist setting. Prevention strategies for Malignant Fibrous Histiocytoma (UPS): Undifferentiated Pleomorphic Sarcoma focus on reducing modifiable risk factors and promoting overall health. Lifestyle interventions such as a balanced diet, regular physical activity, and avoidance of tobacco and excessive alcohol are beneficial. Routine screening and early detection are important where treatment is more effective at early stages.

Go to the ER immediately for a rapidly expanding mass causing acute neurovascular compromise (compartment syndrome, loss of distal pulse) or a pathological fracture at a tumour site. Refer urgently to a sarcoma centre for any unexplained soft tissue mass greater than 5 cm in maximum diameter, any mass deep to the fascia regardless of size, any mass enlarging progressively over weeks, or any new mass arising at a prior radiotherapy site — do not excise outside a specialist setting as unplanned surgery compromises subsequent margin-negative resection. Li-Fraumeni syndrome and NF1 patients require annual whole-body MRI. All treated UPS patients need regular chest CT surveillance, as pulmonary metastases are the predominant site of relapse within 2-3 years.